Cargando…

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients

INTRODUCTION: Clinical trials (CT) on triple therapy against HCV infection in HIV-infected patients including TVR plus pegylated interferon and ribavirin (PR) have reported considerably higher response rates than with PR alone. This study was aimed to evaluate the efficacy and safety of triple thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Los Santos, Ignacio, Montes, Marisa, Sanz-Moreno, Jose, De Miguel, Julio, Sanz-Sanz, Jesus, Gaspar, Gabriel, Perez-Caballero, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Session – Abstract P101
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224774/ https://www.ncbi.nlm.nih.gov/pubmed/25394137 http://dx.doi.org/10.7448/IAS.17.4.19633

Ejemplares similares

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
por: Montes, Marisa, et al.
Publicado: (2014)

L’homéopathie peut-elle diminuer la durée des symptômes des patients suite à une infection COVID-19 ?
por: Saidani, A., et al.
Publicado: (2022)

Impact of covid19 crisis on the emergency management of cardiovascular diseases
por: Olié, V., et al.
Publicado: (2021)

Monitoring renal function during combination therapy with telaprevir in HIV/HCV co-infected patients with advanced/fibrosis cirrhosis
por: Puzzolante, Cinzia, et al.
Publicado: (2014)

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
por: Minguez, Carlos, et al.
Publicado: (2014)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Teeth discolouration and prescribed slimming magistral formula: a case report
por: Fernandes, Tânia, et al.
Publicado: (2021)

DIAGNÓSTICO SITUACIONAL MEDIANTE MONITORAMENTO DA LINHA DE CUIDADO DAS PESSOAS VIVENDO COM HIV/AIDS: UM ESTUDO TRANSVERSAL
por: Bones, Ana Amélia Nascimento da Silva, et al.
Publicado: (2022)

COVID-19 PANDEMIC STRESS AND COMT VAL158MET ON YOUTH EXTERNALIZING BEHAVIOURS: A LONGITUDINAL STUDY FROM THE ADOLESCENT BRAIN COGNITIVE DEVELOPMENT (ABCD) EUROPEAN SUBSAMPLE
por: Kant, Tuana, et al.
Publicado: (2022)

Liver Fibrosis progression using Fibroscan in HIV/HCV coinfected patients with undetectable HIV viral load
por: Perez-Martinez, Laura, et al.
Publicado: (2014)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder
por: Fialho, Renata, et al.
Publicado: (2014)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
por: Neukam, Karin, et al.
Publicado: (2015)

Telescope TVR 11 11 92
Publicado: (1992)

Acute hepatitis C virus (HCV) infection in the setting of HIV coinfection: a single-centre 10-year follow-up
por: Ingiliz, Patrick, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study
por: Flamm, Steven L., et al.
Publicado: (2014)

Analysis of hepatitis non-treatment causes in a cohort of HCV and HCV/HIV infected patients
por: Pereira, Karen, et al.
Publicado: (2014)

Aucune différence de la sévérité de l’infection COVID-19 entre patients traités par rituximab et les autres biothérapies
por: Haddouche, A., et al.
Publicado: (2022)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings
por: Berenguer, Juan, et al.
Publicado: (2018)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Improve screening of HCV infection by targeting high prevalence aged groups: analysis of a cohort of HCV and HIV co-infected patients
por: Brogueira, Pedro, et al.
Publicado: (2014)

Telaprevir
Publicado: (2012)

Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
por: Fanciulli, Chiara, et al.
Publicado: (2022)

Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory
por: Ehret, Robert, et al.
Publicado: (2014)

Facial emotional processing deficits in long-term HIV-suppressed patients
por: Gonzalez-Baeza, Alicia, et al.
Publicado: (2014)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Early results from an Egyptian transcatheter aortic valve registry (Egy-TVR)
por: Bahaa, Hesham, et al.
Publicado: (2021)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study
por: Carrero-Gras, Ana, et al.
Publicado: (2014)

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region
por: Torre, P., et al.
Publicado: (2022)

Effect of HIV infection-related factors on SVR rate in HCV treatment in HIV-infected patients
por: Kravchenko, Alexey, et al.
Publicado: (2014)

Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Association mapping and marker-assisted selection of the lettuce dieback resistance gene Tvr1
por: Simko, Ivan, et al.
Publicado: (2009)

Effect of right and left-sided programmed atrial extrasystoles on conduction across Bachmanns Bundle and initiation of atrial fibrillation
por: Van Schie, M S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2fqhfjrsan0a85hvjlu2jc6rm9